INTRASENSE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.358 EUR | 0.00% |
|
+21.36% | -0.56% |
| Apr. 17 | Intrasense: an innovative solution for cancer monitoring | CF |
| Apr. 09 | Guerbet: CE certificate for a platform | CF |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2022 | 3.79M 4.08M | Sales 2023 | 3.3M 3.56M | Capitalization | 18.8M 20.25M |
|---|---|---|---|---|---|
| Net income 2022 | -3M -3.23M | Net income 2023 | -3M -3.23M | EV / Sales 2022 | 2.85 x |
| Net Debt 2022 | 650K 700K | Net cash position 2023 | 3.06M 3.3M | EV / Sales 2023 | 4.76 x |
| P/E ratio 2022 |
-2.97
x | P/E ratio 2023 |
-5.16
x | Employees | 74 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 44.57% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 week | +21.36% | ||
| Current month | -0.28% | ||
| 1 month | +62.73% | ||
| 3 months | +0.28% | ||
| 6 months | -8.21% | ||
| Current year | -0.56% |
1 week
0.32
0.37
1 month
0.220.44
Current year
0.200.44
1 year
0.200.55
3 years
0.201.02
5 years
0.202.43
10 years
0.194.10
| Managers | Title | Age | Since |
|---|---|---|---|
Nicolas Reymond
CEO | Chief Executive Officer | 42 | 18-02-11 |
Julien Coste
DFI | Director of Finance/CFO | - | - |
Frédéric Champ
CTO | Chief Tech/Sci/R&D Officer | - | 22-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michèle Lesieur
CHM | Chairman | 65 | 20-10-07 |
Patrice Rullier
BRD | Director/Board Member | 63 | 19-03-14 |
Nicolas Reymond
CEO | Chief Executive Officer | 42 | 18-02-11 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-06 | 0.358 | 0.00% | 3 251 |
| 24-05-03 | 0.358 | +2.29% | 36,653 |
| 24-05-02 | 0.35 | -2.51% | 23,811 |
| 24-04-30 | 0.359 | +21.69% | 148,281 |
| 24-04-29 | 0.295 | -6.65% | 75,232 |
Real-time Euronext Paris, May 06, 2024 at 06:32 am EDT
More quotes
Founded in 2004, Intrasense develops and markets a unique medical device named Myrian®, a software platform facilitating and ensuring diagnosis, decision-making and therapeutic follow-up. Thanks to Myrian®, more than 1,200 hospitals and clinics spread over 40 countries use a unique and integrated platform supporting all types of imaging modalities (MRI, scanner...). Enriched with expert clinical modules dedicated to specific pathologies and organs, Myrian® provides a universal medical image processing solution which can be fully integrated into any healthcare information system.
Calendar
2024-07-10
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -0.56% | 20.13M | |
| +8.39% | 218B | |
| +7.05% | 184B | |
| +13.53% | 135B | |
| -0.27% | 62.38B | |
| +11.57% | 51.37B | |
| +7.76% | 50.9B | |
| +1.36% | 40.87B | |
| +2.69% | 36.28B | |
| +25.95% | 31.88B |
- Stock Market
- Equities
- ALINS Stock